Abstract

Excessive cholangiocyte expansion (ductular reaction) promotes liver disease progression, but the underlying mechanism is poorly understood. Here we identify biliary NF-κB-inducing kinase (NIK) as a pivotal regulator of ductular reaction. NIK is known to activate the noncanonical IKKα/NF-κB2 pathway and regulate lymphoid tissue development. We find that cholangiocyte NIK is upregulated in mice with cholestasis induced by bile duct ligation (BDL), 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), or α-naphtyl-isothiocyanate (ANIT). DDC, ANIT, or BDL induces ductular reaction, liver injury, inflammation, and fibrosis in mice. Cholangiocyte-specific deletion of NIK, but not IKKα, blunts these pathological alterations. NIK inhibitor treatment similarly ameliorates DDC-induced ductular reaction, liver injury, and fibrosis. Biliary NIK directly increases cholangiocyte proliferation while suppressing cholangiocyte death, and it also promotes secretion of cholangiokines from cholangiocytes. Cholangiokines stimulate liver macrophages and hepatic stellate cells, augmenting liver inflammation and fibrosis. These results unveil a NIK/ductular reaction axis and a NIK/cholangiokine axis that promote liver disease progression.

Excessive expansion of cholangiocytes in the liver leads to ductular reaction and liver disease. Here, the authors show that genetic ablation, or pharmacological inhibition, of biliary NIK blocks ductular reaction, liver inflammation, and liver fibrosis in mice by modulating secretion of cholangiokines that mediate liver inflammation and fibrosis.

Details

Title
Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice
Author
Zhang, Zhiguo 1   VIAFID ORCID Logo  ; Zhong, Xiao 2 ; Shen, Hong 1 ; Sheng, Liang 1   VIAFID ORCID Logo  ; Liangpunsakul, Suthat 3 ; Lok, Anna S. 4 ; Omary, M. Bishr 5 ; Wang, Shaomeng 6 ; Rui, Liangyou 7   VIAFID ORCID Logo 

 University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
 University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); Xiangya Hospital, Central South University, Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Changsha, China (GRID:grid.452223.0) (ISNI:0000 0004 1757 7615) 
 Indiana University School of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Indianapolis, USA (GRID:grid.257413.6) (ISNI:0000 0001 2287 3919) 
 University of Michigan Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
 University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); Rutgers University, Robert Wood Johnson Medical School, Center for Advanced Biotechnology and Medicine, New Brunswick, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796) 
 University of Michigan Medical School, Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
 University of Michigan Medical School, Department of Molecular & Integrative Physiology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370); University of Michigan Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2708095904
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.